• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Geography Determines Appropriate Use of Imaging in Low-Risk Cancer Patients

Article

The study, published in JAMA Oncology, found that low risk breast and prostate cancer patients received unnecessary imaging overall, with a higher rate observed in the North East region of the country.

Where you receive medical care impacts many things — including whether or not you receive inappropriate medical tests, according to a new study. Researchers from NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, in a new retrospective study publishing online March 12 in JAMA Oncology, conclude that patients with low-risk prostate or breast cancer were more or less likely to receive inappropriate imaging during treatment, depending on the region of the country in which they received medical care.

They examined medical records from 2004-2007 of 9,219 men with low-risk prostate cancer and 30,398 women with low-risk breast cancer, across 84 separate hospital referral regions (HRRs). They conclude that overuse of imaging occurred at a rate of approximately 44.4% for men and nearly 42% for women in the study.

Equally important, inappropriate use of imaging was strongly linked to certain regions across the United States. in which patients were treated. For example, HRRs in the Northeast reported higher use of imaging tests for low-risk patients, while other regions, such as the Northwest and Utah, demonstrated more appropriate use of imaging.

Read the complete press release by NYU Langone Medical Center:

http://bit.ly/1MxZKQ0

Related Videos
Mila Felder, MD, FACEP
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance (COA) and physician and partner of AO Multispecialty Clinic in Augusta, Georgia.
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr Kathi Mooney
Tiago Biachi de Castria, MD, PhD, Moffitt Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.